

Jordi Bruna

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/907078/publications.pdf>

Version: 2024-02-01

141
papers

6,971
citations

81839

39
h-index

66879

78
g-index

147
all docs

147
docs citations

147
times ranked

8686
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 2306.	3.8	1,619
2	Chemotherapy-induced peripheral neurotoxicity (CIPN): An update. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 51-77.	2.0	441
3	The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. <i>Annals of Oncology</i> , 2013, 24, 454-462.	0.6	232
4	Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. <i>Annals of Neurology</i> , 2006, 59, 178-181.	2.8	213
5	Neuronal surface antigen antibodies in limbic encephalitis. <i>Neurology</i> , 2008, 71, 930-936.	1.5	189
6	Clinical pattern and associations of oxaliplatin acute neurotoxicity. <i>Cancer</i> , 2013, 119, 438-444.	2.0	179
7	Chemobrain: A systematic review of structural and functional neuroimaging studies. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 1311-1321.	2.9	152
8	Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. <i>Neuropathology</i> , 2007, 27, 114-120.	0.7	148
9	Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. <i>Annals of Oncology</i> , 2014, 25, 257-264.	0.6	136
10	Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma. <i>JAMA Oncology</i> , 2018, 4, 495.	3.4	135
11	Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 392-398.	0.9	116
12	Syndrome and outcome of antibody-negative limbic encephalitis. <i>European Journal of Neurology</i> , 2018, 25, 1011-1016.	1.7	103
13	Anti-Hu-associated brainstem encephalitis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 80, 404-407.	0.9	95
14	Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial. <i>Neurotherapeutics</i> , 2018, 15, 178-189.	2.1	92
15	Taxane-Induced Peripheral Neurotoxicity. <i>Toxics</i> , 2015, 3, 152-169.	1.6	87
16	Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study. <i>Cancer</i> , 2013, 119, 3570-3577.	2.0	86
17	Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice. <i>Experimental Neurology</i> , 2010, 223, 599-608.	2.0	85
18	Cognitive and Brain Structural Changes in a Lung Cancer Population. <i>Journal of Thoracic Oncology</i> , 2015, 10, 38-45.	0.5	79

#	ARTICLE	IF	CITATIONS
19	Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-2010 in Spain. <i>Neuro-Oncology</i> , 2013, 15, 797-805.	0.6	77
20	Bortezomib-induced peripheral neurotoxicity: an update. <i>Archives of Toxicology</i> , 2014, 88, 1669-1679.	1.9	73
21	Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. <i>Annals of Oncology</i> , 2012, 23, 3116-3122.	0.6	69
22	Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics. <i>Nature Reviews Neurology</i> , 2017, 13, 492-504.	4.9	68
23	Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study. <i>Journal of the Peripheral Nervous System</i> , 2014, 19, 299-306.	1.4	67
24	Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 919-923.	1.1	66
25	Bevacizumab for the Treatment of Glioblastoma. <i>Clinical Medicine Insights: Oncology</i> , 2013, 7, CMO.S8503.	0.6	64
26	Encephalitis Induced by Immune Checkpoint Inhibitors. <i>JAMA Neurology</i> , 2021, 78, 864.	4.5	61
27	Leptomeningeal carcinomatosis. <i>Cancer</i> , 2009, 115, 381-389.	2.0	58
28	Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. <i>Journal of the Peripheral Nervous System</i> , 2010, 15, 17-25.	1.4	57
29	Validation of the new graded prognostic assessment scale for brain metastases: a multicenter prospective study. <i>Radiation Oncology</i> , 2011, 6, 23.	1.2	51
30	Impact of radiotherapy delay on survival in glioblastoma. <i>Clinical and Translational Oncology</i> , 2013, 15, 278-282.	1.2	50
31	Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 383-391.	1.7	49
32	Pathogenesis of platinum-induced peripheral neurotoxicity: Insights from preclinical studies. <i>Experimental Neurology</i> , 2020, 325, 113141.	2.0	49
33	Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. <i>Cancer Treatment Reviews</i> , 2020, 89, 102067.	3.4	48
34	Longitudinal Brain Changes Associated with Prophylactic Cranial Irradiation in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 475-486.	0.5	47
35	Role of flow cytometry immunophenotyping in the diagnosis of leptomeningeal carcinomatosis. <i>Neuro-Oncology</i> , 2012, 14, 43-52.	0.6	46
36	Idiopathic acute transverse myelitis: a clinical study and prognostic markers in 45 cases. <i>Multiple Sclerosis Journal</i> , 2006, 12, 169-173.	1.4	43

#	ARTICLE	IF	CITATIONS
37	Neurotoxicity induced by antineoplastic proteasome inhibitors. <i>NeuroToxicology</i> , 2014, 43, 28-35.	1.4	43
38	Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, jnnp-2019-320969.	0.9	43
39	Immune checkpoint inhibitorsâ€induced neuromuscular toxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S74-S85.	1.4	42
40	Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model. <i>Experimental Neurology</i> , 2014, 253, 165-173.	2.0	39
41	Oxaliplatin-Induced Peripheral Neuropathy and Identification of Unique Severity Groups in Colorectal Cancer. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 701-706.e1.	0.6	39
42	Methods for in vivo studies in rodents of chemotherapy induced peripheral neuropathy. <i>Experimental Neurology</i> , 2020, 325, 113154.	2.0	39
43	Phase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors. <i>Journal of Neuro-Oncology</i> , 2012, 109, 137-142.	1.4	38
44	Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 899-902.	1.1	37
45	Correspondence between neurophysiological and clinical measurements of chemotherapyâ€induced peripheral neuropathy: secondary analysis of data from the CLIPerINomS study. <i>Journal of the Peripheral Nervous System</i> , 2014, 19, 127-135.	1.4	36
46	Neuropathic Pain and Nerve Growth Factor in Chemotherapy-Induced Peripheral Neuropathy: Prospective Clinical-Pathological Study. <i>Journal of Pain and Symptom Management</i> , 2017, 54, 815-825.	0.6	36
47	Cisplatin-induced peripheral neuropathy is associated with neuronal senescence-like response. <i>Neuro-Oncology</i> , 2021, 23, 88-99.	0.6	36
48	Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). <i>European Journal of Cancer</i> , 2013, 49, 2910-2918.	1.3	35
49	Lymphomatosis cerebri: a rare form of primary central nervous system lymphoma. Analysis of 7 cases and systematic review of the literature. <i>Neuro-Oncology</i> , 2016, 18, 707-715.	0.6	35
50	Genetic determinants of chronic oxaliplatinâ€induced peripheral neurotoxicity: a genomeâ€wide study replication and metaâ€analysis. <i>Journal of the Peripheral Nervous System</i> , 2015, 20, 15-23.	1.4	34
51	Proton MR Spectroscopy Provides Relevant Prognostic Information in High-Grade Astrocytomas. <i>American Journal of Neuroradiology</i> , 2011, 32, 74-80.	1.2	33
52	Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 171-177.	1.4	32
53	Epilepsy in glioblastoma patients: basic mechanisms and current problems in treatment. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 333-344.	1.3	31
54	Toxic Effects of Bortezomib on Primary Sensory Neurons and Schwann Cells of Adult Mice. <i>Neurotoxicity Research</i> , 2015, 27, 430-440.	1.3	31

#	ARTICLE	IF	CITATIONS
55	Early post-operative magnetic resonance imaging in glioblastoma: correlation among radiological findings and overall survival in 60 patients. <i>European Radiology</i> , 2016, 26, 1048-1055.	2.3	31
56	Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study. <i>European Journal of Neurology</i> , 2013, 20, 788-794.	1.7	30
57	Bortezomib and other proteasome inhibitors-induced peripheral neurotoxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S52-S62.	1.4	30
58	Thymoma and Autoimmune Encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	28
59	Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy. <i>Journal of Neuro-Oncology</i> , 2012, 108, 451-458.	1.4	27
60	Brain functional connectivity in lung cancer population: an exploratory study. <i>Brain Imaging and Behavior</i> , 2018, 12, 369-382.	1.1	26
61	Chemotherapy-induced peripheral neuropathy: An unresolved issue. <i>Neurología (English Edition)</i> , 2010, 25, 116-131.	0.2	25
62	Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study. <i>Journal of Neuro-Oncology</i> , 2020, 148, 545-554.	1.4	25
63	Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). <i>Neuro-Oncology</i> , 2022, 24, 755-767.	0.6	25
64	Brain damage following prophylactic cranial irradiation in lung cancer survivors. <i>Brain Imaging and Behavior</i> , 2016, 10, 283-295.	1.1	24
65	Meningeal carcinomatosis as the first manifestation of a transitional cell carcinoma of the bladder. <i>Journal of Neuro-Oncology</i> , 2003, 63, 63-67.	1.4	23
66	Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve. <i>Supportive Care in Cancer</i> , 2018, 26, 3143-3151.	1.0	23
67	Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5774.	1.8	23
68	Leptomeningeal Metastases. <i>Current Treatment Options in Neurology</i> , 2012, 14, 402-415.	0.7	22
69	Etiologic Spectrum and Prognosis of Longitudinally Extensive Transverse Myelopathies. <i>European Neurology</i> , 2014, 72, 86-94.	0.6	22
70	Inhibition of the neuronal NF- κ B pathway attenuates bortezomib-induced neuropathy in a mouse model. <i>NeuroToxicology</i> , 2016, 55, 58-64.	1.4	22
71	Cognitive and brain structural changes in long-term oligodendroglial tumor survivors. <i>Neuro-Oncology</i> , 2019, 21, 1470-1479.	0.6	22
72	Evaluation of pre-existing neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model. <i>Journal of the Peripheral Nervous System</i> , 2011, 16, 199-212.	1.4	21

#	ARTICLE	IF	CITATIONS
73	Precise enhancement quantification in post-operative MRI as an indicator of residual tumor impact is associated with survival in patients with glioblastoma. <i>Scientific Reports</i> , 2021, 11, 695.	1.6	21
74	Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity in breast cancer patients. <i>Journal of the Peripheral Nervous System</i> , 2022, 27, 166-174.	1.4	21
75	Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1793-1801.	1.2	20
76	Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 111-119.	1.4	20
77	Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations. <i>Neurosurgery</i> , 2019, 85, E448-E456.	0.6	20
78	Autonomic nervous system and cancer. <i>Clinical Autonomic Research</i> , 2018, 28, 301-314.	1.4	18
79	Refractory nonconvulsive status epilepticus in Creutzfeldt-Jakob disease. <i>Epileptic Disorders</i> , 2010, 12, 239-242.	0.7	17
80	Preradiotherapy MR Imaging: A Prospective Pilot Study of the Usefulness of Performing an MR Examination Shortly before Radiation Therapy in Patients with Glioblastoma. <i>American Journal of Neuroradiology</i> , 2016, 37, 2224-2230.	1.2	17
81	An intrinsic DFF40/CAD endonuclease deficiency impairs oligonucleosomal DNA hydrolysis during caspase-dependent cell death: a common trait in human glioblastoma cells. <i>Neuro-Oncology</i> , 2016, 18, 950-961.	0.6	17
82	Assessing risk factors of falls in cancer patients with chemotherapy-induced peripheral neurotoxicity. <i>Supportive Care in Cancer</i> , 2020, 28, 1991-1995.	1.0	17
83	Reliability and accuracy of quantitative sensory testing for oxaliplatin-induced neurotoxicity. <i>Acta Neurologica Scandinavica</i> , 2015, 131, 282-289.	1.0	16
84	Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics. <i>Journal of Neuro-Oncology</i> , 2018, 136, 533-539.	1.4	16
85	Emerging pharmacological strategies for the management of chemotherapy-induced peripheral neurotoxicity (CIPN), based on novel CIPN mechanisms. <i>Expert Review of Neurotherapeutics</i> , 2020, 20, 1005-1016.	1.4	16
86	Presurgical Identification of Primary Central Nervous System Lymphoma with Normalized Time-Intensity Curve: A Pilot Study of a New Method to Analyze DSC-PWI. <i>American Journal of Neuroradiology</i> , 2020, 41, 1816-1824.	1.2	16
87	Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity. <i>Neurology</i> , 2021, 97, e660-e672.	1.5	16
88	Sigma-1 receptor: a new player in neuroprotection against chemotherapy-induced peripheral neuropathy. <i>Neural Regeneration Research</i> , 2018, 13, 775.	1.6	16
89	Voxel-level analysis of normalized DSC-PWI time-intensity curves: a potential generalizable approach and its proof of concept in discriminating glioblastoma and metastasis. <i>European Radiology</i> , 2022, 32, 3705-3715.	2.3	14
90	Antibodies against disialosyl and terminal NeuNAc(1±2-3)Gal ganglioside epitopes in acute relapsing sensory ataxic neuropathy. <i>Journal of Neurology</i> , 2008, 255, 764-766.	1.8	13

#	ARTICLE	IF	CITATIONS
91	Paraneoplastic Opsoclonus-Myoclonus Syndrome as a New and Single Manifestation of Relapsing Disease in a Patient with Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 968-969.	0.5	13
92	Oxaliplatin Neurotoxicity. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 303-312.	1.0	13
93	Performance monitoring in lung cancer patients pre- and post-chemotherapy using fine-grained electrophysiological measures. <i>NeuroImage: Clinical</i> , 2018, 18, 86-96.	1.4	13
94	Late effects of cancer treatment: consequences for long-term brain cancer survivors. <i>Neuro-Oncology Practice</i> , 2021, 8, 18-30.	1.0	12
95	Seizure-susceptible brain regions in glioblastoma: identification of patients at risk. <i>European Journal of Neurology</i> , 2018, 25, 387-394.	1.7	11
96	Liability of the voltage-gated potassium channel KCNN3 repeat polymorphism to acute oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, 298-303.	1.4	11
97	Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age. <i>Journal of Neuro-Oncology</i> , 2019, 143, 515-523.	1.4	11
98	RNU6-1 in circulating exosomes differentiates GBM from non-neoplastic brain lesions and PCNSL but not from brain metastases. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa010.	0.4	11
99	Meningeal Lymphomatosis as the First Manifestation of Splenic Marginal Zone Lymphoma. <i>International Journal of Hematology</i> , 2005, 82, 63-65.	0.7	10
100	Serum micronutrients and prealbumin during development and recovery of chemotherapy-induced peripheral neuropathy. <i>Journal of the Peripheral Nervous System</i> , 2016, 21, 134-141.	1.4	10
101	Can leptomeningeal myelomatosis be predicted in patients with IgD multiple myeloma?. <i>Journal of Clinical Neuroscience</i> , 2010, 17, 1071-1072.	0.8	9
102	Stroke and carotid occlusion by giant non-hemorrhagic pituitary adenoma. <i>Acta Neurochirurgica</i> , 2011, 153, 2457-2459.	0.9	9
103	Serum neurofilament light chain levels as biomarker of paclitaxel-induced cognitive impairment in patients with breast cancer: a prospective study. <i>Supportive Care in Cancer</i> , 2022, 30, 1807-1814.	1.0	9
104	Synthesis and Validation of a Bioinspired Catechol-Functionalized Pt(IV) Prodrug for Preclinical Intranasal Glioblastoma Treatment. <i>Cancers</i> , 2022, 14, 410.	1.7	9
105	Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 190-206.	2.0	8
106	Real world, open label experience with lacosamide against acute painful oxaliplatin-induced peripheral neurotoxicity. <i>Journal of the Peripheral Nervous System</i> , 2020, 25, 178-183.	1.4	8
107	Duloxetine against symptomatic chemotherapy-induced peripheral neurotoxicity in cancer survivors: a real world, open-label experience. <i>Anti-Cancer Drugs</i> , 2021, 32, 88-94.	0.7	8
108	Differences in cerebrospinal fluid inflammatory cell reaction of patients with leptomeningeal involvement by lymphoma and carcinoma. <i>Translational Research</i> , 2014, 164, 460-467.	2.2	7

#	ARTICLE	IF	CITATIONS
109	Studying Memory Encoding to Promote Reliable Engagement of the Medial Temporal Lobe at the Single-Subject Level. PLoS ONE, 2015, 10, e0119159.	1.1	7
110	Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations. Cancer Management and Research, 2009, 1, 137.	0.9	7
111	Pelvic dyskinesia with an outstanding response to tetrabenazine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 847-848.	2.5	4
112	Voltage-gated sodium channel dysfunction and the search for other satellite channels in relation to acute oxaliplatin-induced peripheral neurotoxicity. Journal of the Peripheral Nervous System, 2019, 24, 360-361.	1.4	4
113	Neuromuscular complications of cancer therapy. Current Opinion in Neurology, 2021, 34, 658-668.	1.8	4
114	Intranasal Administration of Catechol-Based Pt(IV) Coordination Polymer Nanoparticles for Glioblastoma Therapy. Nanomaterials, 2022, 12, 1221.	1.9	4
115	Meningeal melanocytosis: a possibly useful treatment for a rare primary brain neoplasm. Journal of Neurology, 2011, 258, 1169-1171.	1.8	3
116	Plasticity in bilateral hippocampi after a 3-month physical activity programme in lung cancer patients. European Journal of Neurology, 2021, 28, 1324-1333.	1.7	3
117	Inconclusive evidence to support the use of minimally-invasive radiofrequency denervation against chronic low back pain. Annals of Translational Medicine, 2018, 6, 127-127.	0.7	3
118	Perilesional edema in brain metastases as predictive factor of response to systemic therapy in non-small cell lung cancer patients: a preliminary study. Annals of Translational Medicine, 2021, 9, 648-648.	0.7	2
119	Gossypol Treatment Restores Insufficient Apoptotic Function of DFF40/CAD in Human Glioblastoma Cells. Cancers, 2021, 13, 5579.	1.7	2
120	Sensory-motor polyradiculoneuropathy as the first manifestation of sternum bone plasmacytoma only revealed by bone scintigraphy. Neuromuscular Disorders, 2009, 19, 59-61.	0.3	1
121	GEINO 1402: A phase Ib dose-escalation study followed by an extension phase to evaluate safety and efficacy of crizotinib in combination with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma (GB). Annals of Oncology, 2019, 30, v147.	0.6	1
122	MA13.03 Retrospective Study of Intrathecal Therapy for Non-Small Cell Lung Cancer (NSCLC) Patients with Leptomeningeal Carcinomatosis. Journal of Thoracic Oncology, 2019, 14, S300-S301.	0.5	1
123	Sphingolipid metabolism products: potential new players in the pathogenesis of bortezomib-induced neuropathic pain. Annals of Translational Medicine, 2018, 6, S78-S78.	0.7	1
124	O3.04 * COGNITIVE AND STRUCTURAL BRAIN CHANGES ASSOCIATED WITH PROPHYLACTIC CRANIAL IRRADIATION IN LONG TERM SMALL CELL LUNG CANCER SURVIVORS. Neuro-Oncology, 2014, 16, ii5-ii6.	0.6	0
125	Patient Management Problem—Preferred Responses. CONTINUUM Lifelong Learning in Neurology, 2015, 21, 541-556.	0.4	0
126	Patient Management Problem. CONTINUUM Lifelong Learning in Neurology, 2015, 21, 535-540.	0.4	0

#	ARTICLE	IF	CITATIONS
127	P17.02â€€,Diagnostic delay and treatment options of Primary Central Nervous System Lymphoma in the last decade: preliminary results of first 50 patients from two Catalan institutions. Neuro-Oncology, 2016, 18, iv77-iv77.	0.6	0
128	P16.01â€€,Duloxetine in chemotherapy-induced peripheral neuropathy: experience beyond the clinical trial.. Neuro-Oncology, 2016, 18, iv76-iv76.	0.6	0
129	P11.07â€€,Atypical Meningioma: The impact of WHO 2007 criteria. Neuro-Oncology, 2016, 18, iv67-iv67.	0.6	0
130	P14.04â€€,Retreatment with oxaliplatin in CRC is safe in terms of neurotoxicity. Neuro-Oncology, 2016, 18, iv73-iv74.	0.6	0
131	OS1.1 Role of RNU6-1 isolated from circulating exosomes as a differential biomarker for GBM versus non-neoplastic brain lesions and PCNSL. Neuro-Oncology, 2018, 20, iii216-iii217.	0.6	0
132	P05.21 T1-flair to T1-gadolinium MRI ratio as a predictive value of treatment response in non-small-cell lung cancer (NSCLC) patients affected by multiple brain metastases. Neuro-Oncology, 2018, 20, iii307-iii307.	0.6	0
133	Contrast enhancement in low grade gliomas: A classic prognostic factor in the molecular age. Annals of Oncology, 2018, 29, viii129.	0.6	0
134	Corrigendum. Neuro-Oncology, 2018, , .	0.6	0
135	OS3.3 Radiological characteristics and natural history of adult IDH wild type astrocytomas with TERT promoter mutations. Neuro-Oncology, 2018, 20, iii221-iii221.	0.6	0
136	P10.04 Incidence and characteristics of neurological adverse events secondary to immunotherapy with checkpoint inhibitors. Neuro-Oncology, 2019, 21, iii41-iii41.	0.6	0
137	P14.93 The utility of the brain 18-FDG-PET and perfusion magnetic resonance imaging in the radionecrosis differential diagnosis. Neuro-Oncology, 2019, 21, iii89-iii90.	0.6	0
138	P1.01-111 ATEZO-BRAIN, A Single-Arm Phase II Study of Atezolizumab Combined with Chemotherapy in Stage IV NSCLC Patients with Untreated Brain Metastases. Journal of Thoracic Oncology, 2019, 14, S405.	0.5	0
139	Senescence in neurons: an open issue. Aging, 2021, 13, 16902-16903.	1.4	0
140	Prospective validation of the new graded prognostic assessment scale for brain metastases: A multicenter study.. Journal of Clinical Oncology, 2010, 28, 2074-2074.	0.8	0
141	Duloxetine in symptomatic chemotherapy-induced peripheral neuropathy: Single-center experience beyond the clinical trial.. Journal of Clinical Oncology, 2015, 33, e20713-e20713.	0.8	0